Brought to you by 
ALS TDI, California Stem Cell ally in ALS treatment
22 Aug 2008
Executive Summary
The ALS Therapy Development Institute (ALS TDI) and start-up California Stem Cell (human embryonic stem cell therapies) have allied in a long-term R&D collaboration to advance stem cell therapies for amyotrophic lateral sclerosis (ALS), a fatal neurodegenerative condition also known as Lou Gehrig's disease.
Deal Industry
- Pharmaceuticals
- Research, Analytical Equipment & Supplies
-
Biotechnology
- Gene Therapy, Cell Therapy
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
ALS TDI, California Stem Cell ally in ALS treatment
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice